

# Julia Stowe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4310770/publications.pdf>

Version: 2024-02-01

51  
papers

9,513  
citations

182225

30  
h-index

214428

50  
g-index

63  
all docs

63  
docs citations

63  
times ranked

12244  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained Declines in Age Group-Specific Rotavirus Infection and Acute Gastroenteritis in Vaccinated and Unvaccinated Individuals During the 5 Years Since Rotavirus Vaccine Introduction in England. <i>Clinical Infectious Diseases</i> , 2022, 74, 437-445.	2.9	5
2	Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England. <i>Lancet Regional Health - Europe</i> , The, 2022, 13, 100260.	3.0	35
3	Disease severity during SARS-COV-2 reinfection: a nationwide study. <i>Journal of Infection</i> , 2022, 84, 542-550.	1.7	49
4	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350.	13.9	501
5	Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. <i>Nature Medicine</i> , 2022, 28, 831-837.	15.2	284
6	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1532-1546.	13.9	1,709
7	Effectiveness of BNT162b2 against COVID-19 in adolescents. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 581-583.	4.6	52
8	Characteristics associated with COVID-19 vaccine uptake among adults aged 50 years and above in England (8 December 2020â€“17 May 2021): a population-level observational study. <i>BMJ Open</i> , 2022, 12, e055278.	0.8	18
9	Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 384-392.	2.7	43
10	Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12698.	1.0	8
11	COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 931-933.	4.6	133
12	Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform. <i>Vaccine</i> , 2022, 40, 4479-4487.	1.7	17
13	Guillain-BarrÃ© syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study. <i>BMJ Neurology Open</i> , 2022, 4, e000309.	0.7	9
14	Impact of Extending the Timing of Maternal Pertussis Vaccination on Hospitalized Infant Pertussis in England, 2014â€“2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e2502-e2508.	2.9	17
15	Stillbirths During the COVID-19 Pandemic in England, April-June 2020. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 86.	3.8	70
16	Investigation of a pertussis outbreak and comparison of two acellular booster pertussis vaccines in a junior school in South East England, 2019. <i>Eurosurveillance</i> , 2021, 26, .	3.9	8
17	COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. <i>Lancet</i> , The, 2021, 397, 1725-1735.	6.3	658
18	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. <i>BMJ</i> , The, 2021, 373, n1088.	3.0	881

#	ARTICLE	IF	CITATIONS
19	Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. <i>International Journal of Epidemiology</i> , 2021, 50, 1124-1133.	0.9	124
20	Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis. <i>Vaccine</i> , 2021, 39, 4500-4509.	1.7	4
21	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594.	13.9	2,411
22	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. <i>Nature Communications</i> , 2021, 12, 7217.	5.8	80
23	National Outbreak of Pertussis in England, 2011–2012: A Case-control Study Comparing 3-Component and 5-Component Acellular Vaccines With Whole-cell Pertussis Vaccines. <i>Clinical Infectious Diseases</i> , 2020, 70, 200-207.	2.9	14
24	Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy. <i>CNS Drugs</i> , 2020, 34, 1-8.	2.7	21
25	Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study. <i>PLoS Medicine</i> , 2020, 17, e1003225.	3.9	6
26	The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis. <i>Vaccine</i> , 2020, 38, 4935-4939.	1.7	14
27	Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: An ecological study. <i>Vaccine</i> , 2020, 38, 4816-4819.	1.7	6
28	Infant Hospitalizations and Fatalities Averted by the Maternal Pertussis Vaccination Program in England, 2012–2017: Post-implementation Economic Evaluation. <i>Clinical Infectious Diseases</i> , 2020, 71, 1984-1987.	2.9	14
29	Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. <i>BMC Medicine</i> , 2018, 16, 13.	2.3	76
30	No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. <i>Vaccine</i> , 2017, 35, 1729-1732.	1.7	52
31	Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted. <i>Vaccine</i> , 2017, 35, 680-686.	1.7	51
32	No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001-2002. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1248-1250.	2.0	21
33	The risk of intussusception following monovalent rotavirus vaccination in England: A self-controlled case-series evaluation. <i>Vaccine</i> , 2016, 34, 3684-3689.	1.7	68
34	The risk of intussusception following monovalent rotavirus vaccination in England: A self-controlled case-series evaluation Ref. No: JVAC-D-16-01124. <i>Vaccine</i> , 2016, 34, 6115.	1.7	17
35	Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England. <i>Sleep</i> , 2016, 39, 1051-1057.	0.6	44
36	The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. <i>Journal of Infection</i> , 2016, 73, 241-253.	1.7	41

#	ARTICLE	IF	CITATIONS
37	Rapid Declines in Age Groupâ€“Specific Rotavirus Infection and Acute Gastroenteritis Among Vaccinated and Unvaccinated Individuals Within 1 Year of Rotavirus Vaccine Introduction in England and Wales. <i>Journal of Infectious Diseases</i> , 2016, 213, 243-249.	1.9	76
38	Clinical features of narcolepsy in children vaccinated with <scp>AS</scp>03 adjuvanted pandemic <scp>A</scp>/<scp>H</scp>1<scp>N</scp>1 2009 influenza vaccine in <scp>E</scp>ngland. <i>Developmental Medicine and Child Neurology</i> , 2014, 56, 1117-1123.	1.1	44
39	Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. <i>BMJ, The</i> , 2013, 346, f794-f794.	3.0	254
40	The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. <i>Journal of Infection</i> , 2012, 65, 17-24.	1.7	200
41	Guillainâ€“BarrÃ© syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: Self-controlled case series. <i>Vaccine</i> , 2011, 29, 7878-7882.	1.7	46
42	Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: A database study. <i>Vaccine</i> , 2011, 29, 9467-9472.	1.7	20
43	Guillain-BarrÃ© syndrome and H1N1 influenza vaccine in UK children. <i>Lancet, The</i> , 2011, 378, 1545-1546.	6.3	16
44	Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. <i>Lancet, The</i> , 2009, 374, 2115-2122.	6.3	231
45	Idiopathic thrombocytopenic purpura and the second dose of MMR: Figure 1. <i>Archives of Disease in Childhood</i> , 2008, 93, 182-183.	1.0	34
46	Investigation of the Temporal Association of Guillain-Barre Syndrome With Influenza Vaccine and Influenzalike Illness Using the United Kingdom General Practice Research Database. <i>American Journal of Epidemiology</i> , 2008, 169, 382-388.	1.6	159
47	Post-Licensure Safety of the Meningococcal Group C Conjugate Vaccine. <i>Hum Vaccin</i> , 2007, 3, 59-63.	2.4	12
48	No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. <i>Archives of Disease in Childhood</i> , 2007, 92, 887-889.	1.0	33
49	Bellâ€™s Palsy and Parenteral Inactivated Influenza Vaccine. <i>Hum Vaccin</i> , 2006, 2, 110-112.	2.4	41
50	Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association. <i>Pediatrics</i> , 2004, 114, 584-591.	1.0	223
51	Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England. <i>Nature Medicine</i> , 0, , .	15.2	6